The INNOTEST® PHOSPHO-TAU(181P) is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF).
The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-5). The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181) (6-7).
Art. no. 81574 (96T – CE-IVD) - see also Art. no. 81581 (96T - RUO) - Please contact your local Fujirebio representative for the availability of this product in your country.
Features & Benefits
- User-friendly enzyme immunoassay, standard technology
- Generic and color-coded components
- Easily automated on microplate processor (generic components)
- Ready-to-use Calibrators reduce inter and intra run variation
- Run Validation Controls for assay run validation
- Sample volume: 75 µL CSF. Duplicate testing is strongly recommended and requires 2 x 75 µL CSF.
- Limit of Detection: 13 pg/mL
Calibrator range: 15,6 to 1000 pg/mL
- This assay should be used in combination with the PHOSPHO-TAU CAL-RVC pack, article no. 81575.
- Andreasen et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
- Hansson et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
- Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-393.
- Tabaraud et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012; 125(6): 416-23
- Buchhave et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.
- Vanmechelen et al. CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B. Alzheimer’s disease: Advances in etiology, pathogenesis and therapeutics. Chichester: John Wiley & Sons; 2001. p. 285-291.
- De Vreese et al. Discrimination of dementia with Lewy bodies from Alzheimer’s disease via determination of the phospho-tau concentration in cerebrospinal fluid. 18th International Conference of Alzheimer’s Disease. Barcelona, Spain, October 23-26, 2002.
Additional useful information about Alzheimer’s disease can be found on the following websites:
The Alzheimer forum site:
These resources are either available in free access or for users holding a Premium eServices account: